EyePoint Pharmaceuticals Reports Incentive Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Aug. 16, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company focused on developing and commercializing therapies to improve the lives of patients with serious retinal diseases, today announced that the company has granted fringe stock options to new employees as incentive awards outside of the company’s Long-Term Incentive Plan for 2023, in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company has granted stock options to purchase up to an aggregate of 106,600 shares of EyePoint Pharmaceuticals common stock to nine new employees. The stock options were granted on August 15, 2024. The grants were approved by the Compensation Committee and are made as an incentive for each employee joining EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option grants have an exercise price of $8.20 per share, the closing price of EyePoint Pharmaceuticals common stock on August 15, 2024. The options have a term of ten years and vest over four years, with 25% of the initial number of shares vesting on the first anniversary of the applicable employee’s grant date and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued employment with EyePoint Pharmaceuticals through the applicable vesting dates.